- The histopathologic subtype of basal cell carcinoma (BCC) is not associated with response rate to oral vismodegib, according to a small, phase 2b study.
Why this matters
- The effect of subtype on response to vismodegib, previously demonstrated in the ERIVANCE trial, was unclear.
- Clinical response rates:
- 20% complete response,
- 41.5% partial response,
- 36.9% stable disease, and
- 1.5% progressive disease.
- At 24 weeks, most BCCs achieved histologic clearance, with positive biopsies in:
- 10.5% of target lesions,
- 30.4% of nontarget lesions, and
- 21.4% overall.
- No statistical differences in histologic clearance rates were seen between histopathologic subtypes.
- The most common treatment-emergent adverse events were dysgeusia/loss of taste (86%), muscle spasms (82%), and alopecia (71%).
- 27 patients with BCC who received vismodegib were included.
- Patients had 27 target lesions (15 infiltrative, 5 nodular, 7 superficial) and 38 nontarget lesions (9 infiltrative, 3 superficial, 24 nodular, 2 keratotic).
- Funding: Genentech/Roche.
- Small patient sample size.
- Open-label trial.